Literature DB >> 11128669

Primary antiphospholipid syndrome: functional outcome after 10 years.

D Erkan1, Y Yazici, R Sobel, M D Lockshin.   

Abstract

OBJECTIVE: To analyze the 10 year functional outcome of primary antiphospholipid syndrome (APS).
METHODS: We identified 39 patients with primary APS (35 female, 4 male) who developed a first thrombotic or pregnancy event before 1990. Patients meeting American College of Rheumatology criteria for systemic lupus erythematosus or other connective tissue disorders (secondary APS) were excluded. Medical records were reviewed for detailed histories and functional outcomes.
RESULTS: At 10 years' followup, 15 patients (38.4%) had organ damage in the form of hemiparesis (n = 8), dementia (n = 3), quadriplegia (n = 1), dilated cardiomyopathy-myocardial infarction (n = 1), vascular insufficiency-massive pulmonary infarction (n = 1), and endstage renal disease (n = 1). Eight patients (20.5%) with organ damage were unable to perform everyday activities important to their quality of life (functionally impaired). Causes of functional impairment were cognitive dysfunction (n = 3), cardiovascular disease (New York Heart Association Functional Classification Class IV) (n = 2), aphasia (n = 1), expressive aphasia (n = 1), and locked-in syndrome (n = 1).
CONCLUSION: Functional prognosis is poor in an important minority of primary APS patients with > 10 years of disease. One-third of primary APS patients had organ damage and one-fifth were functionally impaired.

Entities:  

Mesh:

Year:  2000        PMID: 11128669

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  20 in total

Review 1.  Renal involvement in antiphospholipid syndrome.

Authors:  Francisco Vileimar Andrade de Azevedo; Diego Germano Maia; Jozelio Freire de Carvalho; Carlos Ewerton Maia Rodrigues
Journal:  Rheumatol Int       Date:  2018-05-05       Impact factor: 2.631

2.  Therapy: Antiphospholipid syndrome research needs more collaboration.

Authors:  Doruk Erkan; Michael D Lockshin
Journal:  Nat Rev Rheumatol       Date:  2014-03-11       Impact factor: 20.543

Review 3.  Antiphospholipid syndrome: frequency, main causes and risk factors of mortality.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Nat Rev Rheumatol       Date:  2010-04-13       Impact factor: 20.543

Review 4.  Renal involvement in antiphospholipid syndrome.

Authors:  Guillermo J Pons-Estel; Ricard Cervera
Journal:  Curr Rheumatol Rep       Date:  2014-02       Impact factor: 4.592

Review 5.  The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus.

Authors:  Ozan Ünlü; Stephane Zuily; Doruk Erkan
Journal:  Eur J Rheumatol       Date:  2015-12-29

Review 6.  Cognitive dysfunction in the patient with antiphospholipid antibodies: considerations for cause and treatment.

Authors:  Melanie J Harrison; Lisa D Ravdin
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

7.  The challenges of antiphospholipid syndrome: experience from diagnosis to self-care.

Authors:  Kathryn Larmour; Gareth Lewis; Gary Benson; Jennifer Hanko
Journal:  BMJ Case Rep       Date:  2014-06-26

8.  The optimal tool for assessment of organ damage in antiphospholipid syndrome.

Authors:  Medha Barbhaiya; Doruk Erkan
Journal:  J Rheumatol       Date:  2013-01       Impact factor: 4.666

9.  Long term outcome of catastrophic antiphospholipid syndrome survivors.

Authors:  D Erkan; R A Asherson; G Espinosa; R Cervera; J Font; J-C Piette; M D Lockshin
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

Review 10.  The Heart and APS.

Authors:  Mary-Carmen Amigo
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.